B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $7.00

PDS Biotechnology (NASDAQ:PDSB) had its price target trimmed by B. Riley from $9.00 to $7.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

Other research analysts have also issued reports about the stock. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Friday, November 15th. Finally, StockNews.com lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Stock Up 1.9 %

Shares of PDS Biotechnology stock opened at $2.15 on Monday. PDS Biotechnology has a 12-month low of $1.53 and a 12-month high of $6.68. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a 50 day moving average price of $3.06 and a two-hundred day moving average price of $3.17. The stock has a market capitalization of $80.43 million, a P/E ratio of -1.85 and a beta of 1.93.

Institutional Trading of PDS Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of PDSB. Vanguard Group Inc. grew its position in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares in the last quarter. Blair William & Co. IL lifted its position in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares during the period. Tempus Wealth Planning LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth approximately $55,000. Cubist Systematic Strategies LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth approximately $146,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $115,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.